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Abstract 
Background 
Insulin resistance (IR) is a significant risk factor in the pathogenesis of type 2 diabetes. 
This research presents pilot study results of the Dynamic Insulin Sensitivity and Secretion 
Test (DISST), a high-resolution, low-intensity test to diagnose insulin sensitivity (IS) and 
characterise pancreatic insulin secretion in response to a (small) glucose challenge. This 
pilot study examines the effect of glucose and insulin dose on the DISST, and tests its 
repeatability. 
Methods 
DISST tests were performed on 16 subjects randomly allocated to low (5g glucose, 0.5U 
insulin), medium (10g glucose, 1U insulin) and high dose (20g glucose, 2U insulin) 
protocols. Two or three tests were performed on each subject a few days apart. 
Results 
Average variability in IS between low and medium dose was 10.3% (P=0.5) and between 
medium and high dose 6.0% (P=0.87). Geometric mean variability between tests was 
6.0% (multiplicative standard deviation MSD 4.9%). Geometric mean variability in first 
phase endogenous insulin response was 6.8% (MSD 2.2%). Results were most consistent 
in subjects with low IS. 
Conclusions 
These findings suggest that DISST may be an easily performed dynamic test to quantify 
IS with high resolution, especially amongst those with reduced IS.  
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Introduction 
Insulin resistance (IR) is a key underlying abnormality in type 2 diabetes and a major risk 
factor for cardiovascular disease (1, 2). A long-term follow-up study by Martin et al. (3) 
reported that 10 years ahead of a formal diagnosis of type 2 diabetes, those who 
developed the disease had 60% higher mean IR than those that did not. McLaughlin et al. 
(4) found that amongst obese individuals IR is the strongest predictor of subsequent type 
2 diabetes and cardiovascular disease risk. 
 
Insulin Sensitivity (IS=1/IR) is not a discrete metric, but represents an attempt to quantify 
insulin mediated glucose utilization. The relative contributions of the three major 
determinants of overall IS (peripheral sensitivity, hepatic sensitivity, β-cell function) vary 
according to whether an individual is in the fasting or postprandial state and may change 
over time as the disease state progresses (5). Methods of assessment vary in their ability 
to determine one, two or three of the contributors, thus generating potentially discrepant 
results requiring careful interpretation (6). 
 
The Euglycaemic Hyperinsulinaemic Clamp (EIC) (7) is the gold-standard for assessing 
insulin sensitivity. It measures peripheral sensitivity by suppressing endogenous glucose 
production (EGP) and endogenous insulin secretion using high dose infusions of insulin 
and glucose. Due to its complexity and duration (6, 8), simpler methods have arisen, 
including the Insulin Tolerance Test (ITT) (9) and the Intravenous Glucose Tolerance 
Test (IVGTT) with minimal model assessment (10). These tests have not achieved wide 
acceptance in a clinical environment given that they too are time consuming and complex 
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and do not correlate particularly well with the EIC (8, 9). Other attempts at sample 
reduced (12 sample (11)), or shorter (40 minute (12)) IVGTT protocols had the same 
model identification problems as the standard IVGTT (13), as they too are based on 
minimal model assessment. Simple, fasting assessments HOMA (14) and QUICKI (15), 
are appealing for large studies, however they assess combined hepatic and peripheral 
sensitivities in the fasting state, have poor reproducibility, and do not correlate well with 
the EIC. A sensitive, simple, repeatable measure of insulin sensitivity would have 
considerable value in clinical and research contexts, and in evaluating the impact of 
interventions (16).  
 
The Dynamic Insulin Sensitivity and Secretion Test (DISST) is a dynamic test with 
mathematical model assessment, similar to the insulin modified IVGTT. The integrated 
design of the clinical protocol, mathematical model and data fitting methods enable a 
shorter test duration, more physiological dosing, less frequent sampling, and higher 
robustness, compared with the EIC or IVGTT. In addition to a combined metric for 
hepatic and peripheral insulin sensitivity, detailed information about β-cell function can 
also be obtained (17). During DISST development, a strong emphasis has been put on 
practical aspects of the protocol and clinical applicability, which differentiates it from the 
IVGTT. A more detailed explanation of the test design considerations and differences to 
the IVGTT are given in Appendix A. 
 
The DISST has been designed and tested in Monte Carlo simulation studies (18) and 
shown good accuracy in repeatability with an intra-individual coefficient of variation of 
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4.5% (90%CI: 3.8% - 5.7%). As no simulation study can fully reproduce all metabolic 
effects in such a dynamic test, limited in vivo testing was required prior to the design of a 
full validation study. This pilot study was undertaken to qualitatively verify these 
simulation results in vivo, to assess the effect of glucose and insulin dosing on the 
outcome metrics and to get an indication of the repeatability of the test in an outpatient 
setting. This pilot study does not intend to deliver a fully powered result on the DISST’s 
performance, but rather deliver an indication of feasibility of the test prior to a larger 
validation study against the EIC. A power calculation for a full validation study 
comparing the DISST to the EIC is proposed based on this study’s results. 
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Methods 
Subjects 
A total of 16 adult volunteers were recruited by advertisements in the hospital and word 
of mouth. Subject 12 did not complete the full study protocol and was excluded from all 
further analysis. Insulin samples in two tests (two on subject 6 and two on subject 9) were 
exceptionally high, suggesting sampling errors and were therefore excluded. Subject 9 
had to be excluded completely, as only a single remaining test was available. One subject 
was previously diagnosed with type 2 diabetes and on Metformin treatment. Medication 
was stopped a day prior to the testing. Written informed consent was obtained from all 
subjects, and height, weight and family history of diabetes recorded. Subject 
characteristics are summarised in Table 1.  
Study Design 
All tests were performed at the Christchurch School of Medicine or the Department of 
Human Nutrition, University of Otago using exactly the same protocol. The clinical pilot 
study of the DISST aimed to investigate two aspects: 
• Part 1: Effect of glucose and insulin dose on test outcome 
• Part 2: Repeatability of the test at the same dose 
In Part 1, the subjects had two tests on different days (3-8 days apart) using different 
glucose and insulin doses. Three dosing regimens were used: 5g glucose and 0.5U insulin 
(low), 10g glucose and 1U insulin (medium), or 20g glucose and 2U insulin (high). Each 
subject had a combination of either low/medium or medium/high dose tests. 
In Part 2, the subjects had two tests (3-14 days apart) using the same glucose/insulin 
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dose. Some subjects had three tests and were included in both parts of the study by 
repeating one of the dosing options. The order of the tests on each individual was picked 
randomly, and Table 1 shows the doses given to each subject. 
Experimental Protocol 
The tests were performed in the morning after an overnight fast. A cannula was inserted 
in the antecubital fossa for venous blood sampling and administration of glucose and 
insulin. The catheter was flushed with saline after every sampling or injection step to 
reduce sample contamination. Two baseline blood samples were taken at t=-10 min and 
t=0 minutes. Glucose (50% dextrose) was administered at t=0 min, and insulin (Actrapid, 
NovoNordisk) at t=10 min. Blood samples were taken at t=5, 10, 15, 20, 25, 30, 35, and 
45 minutes to assess the physiological response to the administered glucose and insulin. 
Blood samples were assayed for plasma glucose, insulin and C-peptide concentrations. 
Glucose was analysed by an enzymatic glucose hexokinase assay (C8000 Analyzer, 
Abbott Laboratories, Inc). Insulin and C-peptide were analysed with an ECLIA 
immunoassay (Roche Diagnostics Elecsys). 
 
Modelling and Data Analysis 
Sampled concentration profiles were analysed by fitting metabolic models of glucose, 
insulin and C-peptide to the data, as described in detail in (18-20) and in Appendix B. 
The estimated model parameter value for IS, SI, was used to describe the body’s insulin 
sensitivity. In addition to IS, information about β-cell function (basal secretion, first 
phase response) and hepatic insulin clearance were obtained. 
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For added robustness, glucose samples taken within ten minutes of glucose injection, and 
insulin samples taken within ten minutes of insulin administration, were disregarded in 
the model fit to minimise errors introduced by effects of intravascular mixing (21). This 
approach avoids over-fitting of measurement errors, which can cause considerable 
parameter estimation problems (13, 20).   
Statistical analysis 
The inter-dose repeatability of Part 1 of this study is calculated as the relative percentile 
difference in the insulin sensitivity parameter SI of the higher dose test compared to the 
lower dose test, as shown in Equation 1. The mean result is taken if more than one test 
was done at a given dose. 
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The variability in SI at a given dose for Part 2 is defined as the maximum deviation from 
the mean SI, divided by the mean SI, as shown in Equation 2.  
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Where data distribution is normal, the mean and standard deviation (SD) are used to 
describe spread. Where the distribution is log-normal, the geometric mean and 
multiplicative standard deviation (MSD) are used. Statistical significance of the 
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differences is assessed with the two sample t-test.  
 
Accuracy of the DISST is compared to the intra-individual coefficient of variation CV in 
SI, defined as the ratio of SD over the mean SI (CV=SD/mean-SI), simulated by Monte 
Carlo analysis on a virtual cohort generated from 146 euglycaemic clamp tests (18). The 
CV derived from the Monte Carlo analysis gives an indication of expected accuracy in a 
clinical testing environment. By comparing the simulated CV with the experimentally 
derived accuracy, an estimate is obtained of the variability attributable to other 
physiological factors not completely accounted for by the simulation method. In this pilot 
study a meaningful intra-individual CV in SI cannot be calculated due to only two or 
three tests being performed on each subject. Instead, the absolute deviations of the test 
results ΔSI are compared to the range defined by ±2 SD (95% of subjects) obtained from 
the Monte Carlo results (18). Despite this limitation, this comparison aims to deliver an 
indication of the achievable accuracy in an in-vivo environment, and the validity of the 
prior simulation study. 
 
Ethical approval for the study was granted by the Upper South A Regional Ethics 
Committee. 
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Results 
Part 1 – Effect of dosing 
The estimated IS parameter, SI, is shown in Table 2 for Part 1 (by dose combination), 
along with basal insulin secretion rate uB, first phase insulin secretion AUC10 and peak 
secretion rate Smax. Differences in SI, AUC10 and Smax shown (denoted by Δ) are percentile 
difference of the higher dose result compared to the lower dose result.  
 
Estimated SI is lower in 8/12 subjects at the higher dose test, but the differences are not 
statistically significant (low/medium P=0.50, medium/high P=0.87). A noticeable 
reduction in the impact of dosing can be seen on subjects with lower insulin sensitivity, 
as shown in the correlation plot in Figure 1. Basal insulin secretion uB was consistently 
higher in subjects with lower SI. Total first phase insulin secretion above basal, AUC10, is 
increased at the higher dose in all but one subject, with a wide range in changes of -7.1% 
to 213.8%. The same is the case for the difference in peak secretion rate, Smax, which is in 
the range of -20.7% to 180.9%, and positive for all but two subjects. 
Part 2 – Repeatability 
The study population for Part 2 consisted of 8 subjects, 4 of which completed two low 
dose, and 4 completed two or three medium dose tests. The estimated IS parameter, SI, 
error in SI and insulin secretion metrics are given in Table 3. 
 
Variations in SI are in the range 0.2% to 24.7% with a geometric mean of 6% (MSD 
4.9%). The repeat tests at each dose were insignificantly different to the first tests (low 
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dose P=0.75, medium dose P=0.56). Insulin secretion metrics are very consistent, with 
repeatability in basal secretion rate uB in the range of 2.6% to 11.7%. Total first phase 
insulin AUC10 was estimated with high accuracy in repeatability, with a geometric mean 
value of 6.8% (MSD 2.2%) and a range of 2.9% - 33.1%, and repeatability in Smax 
resulted in a geometric mean of 7.4% (MSD 2.8%), with a range of 1.0% - 25.3%. The 
dependency of dosing on insulin sensitivity in Part 1 is evident in repeatability accuracy 
as well, but is less marked across the SI range, as shown in Figure 2. 
Diagnostic relevance 
Results from the full test protocol analysis on three subjects, including Normal Glucose 
Tolerant (NGT), Impaired Fasting Glucose (IFG) and Type 2 Diabetes (Type2) is shown 
in Appendix C with a full discussion of the potential diagnostic relevance. 
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Discussion 
The goal of this pilot study was to assess the feasibility and performance of the DISST in 
a clinical setting. The modelling and data fitting methods have been customised to a 
clinical protocol to allow robust parameter identification and avoid the problems 
encountered with the IVGTT (13, 22, 23). The study demonstrated a high level of 
acceptability of the test to participants, the only complaint being mild discomfort during 
the injection of 20g glucose, probably due to the large volume injected within a short 
time frame.  This did not occur at lower doses. 
 
The protocol and fitting algorithm proved to be reliable and robust. In Part 1 of the study, 
estimated SI was lower in 8/12 subjects in the higher dose test as compared with the lower 
dose test, but the difference was not statistically significant (P=0.50, P=0.87). This effect 
has also been found by Prigeon et al. (24) who reported lower IS values when an IVGTT 
was performed at different doses. In that study, injecting 4U of insulin resulted in a 32% 
reduced IS value compared with injecting 2U of insulin. A possible explanation could be 
saturation effects, which have been identified in other studies (8, 24, 25). Saturation 
effects are less likely at lower doses, and this aspect could be improved by adding 
saturation dynamics to the model (25, 26). 
 
This pilot study does not permit definitive conclusions with regard to optimum dose. A 
higher dose provides a stronger signal in the sampled concentration profiles but 
encounters stronger saturation effects and triggers stronger suppression of endogenous 
glucose production (EGP), thus adding unknown variability. Suppression of EGP cannot 
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be measured easily and thus is not accounted for in the model. On the other hand a lower 
dose is less likely to be affected by saturation and counter-regulatory responses but might 
be too small to provide an optimum signal. Lower doses are likely to be more 
physiological and involve less discomfort to the subject. In the clinical context, 
consistency is useful and a low to medium dose is probably the best choice.  
 
The reason for the choice of a single dose across all subjects is practical, as it would 
allow a test kit to be compiled prior to knowing the subject’s characteristics. This 
consistency is particularly useful in routine clinical testing environments. It is debatable 
whether a patient specific dose calculation should be used in such a test. However, in this 
study, differences in estimated SI at different dosing in the same subject had a stronger 
effect on lighter subjects with a body weight of less than 70kg, in which estimated SI was 
much lower at the higher dose. On all other subjects the effect was not systematic. It is 
unclear whether this effect is caused by the difference in weight or the fact that these 
lighter subjects were very insulin sensitive and thus more sensitive to assay error or 
measurement noise. A larger study is required to further analyse this aspect. 
 
A further factor that could influence insulin sensitivity in a person is pain induced by the 
protocol, such as cannulation or administration of large volume 50% glucose solution. 
Pain has been shown to affect insulin sensitivity (27, 28) and would add an unknown 
inaccuracy to the assessment. In this study, one person experienced discomfort during 
administration of 20g of glucose, but not in the lower dose. By using a lower, more 
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physiological dose, and more diluted glucose solutions, this effect could potentially be 
mitigated. 
 
Part 2 assessed repeatability by performing the same low or medium dose test on each 
subject two or three times. Errors around the mean in each subject were in the range of 
0% − 25%, and log-normally distributed, with a geometric mean of 6.0% (MSD 4.9). The 
expected intra-individual accuracy assessed by the Monte Carlo simulation (18) resulted 
in a mean CVSI−MC= 4.5% (90%CI: 3.8-5.7%) at the medium dose, CVSI−MC= 6.9% 
(90CI: 4.9-9.9%) at the low dose, and CVSI−MC= 3.6% (90%CI: 3.0-4.5%) at the high 
dose. In other words, considering ±2 SD, an absolute deviation between 6.0-19.8% from 
the mean can be attributable to assay and protocol errors in ~95% of subjects. This 
outcome is also reflected in the hypothesis testing (P=0.75, P=0.56), indicating that 
repeatability of the DISST is good, even with the limited small sample size of this study. 
 
Natural variability in IS, which was not included in the Monte Carlo simulation, can be a 
source of additional variability in this pilot study (29). Results of this study are thus in 
good accordance with the Monte Carlo simulation results, though possibly slightly more 
variable due to additional sources of variability, such as time of day (29), state of health 
(30, 31), menstrual cycle (32) or exercise (33, 34). Glucose samples were analysed in the 
lab with an assay CV=1-2% similar to that simulated in the Monte Carlo study. If point of 
care glucose sensors were used with higher inaccuracies of CV=2-8%, one could think 
that estimated IS could be slightly less repeatable. Due to the integrals involved in the 
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model fitting method (35), this impact is minimized if the variability is assumed to be 
normally distributed around the mean.  
 
The data in Figure 2 suggest more consistency in SI at lower IS ranges. This effect is 
partly attributed to insulin and glucose assay variability, which carry over into the model. 
A dominant effect influencing the estimation of SI in the modelling methodology is the 
decay rate of insulin concentrations immediately following the insulin injection. A 
smaller rate, as generally observed in insulin resistant subjects, is less affected by assay 
variability and results in a more consistent IS assessment. This increased accuracy in less 
sensitive subjects is a positive characteristic of the test, as these subjects represent the 
group amongst whom repeatability and accuracy are clinically the most relevant. In 
contrast to the DISST, the IVGTT can be much less sensitive in markedly insulin 
resistant individuals and those with diabetes (13, 22, 23). 
 
In addition to IS, β-cell secretion metrics are estimated with the DISST from C-peptide 
concentrations (see Appendix B). Secretion metrics were estimated with good 
consistency, given assay errors. While basal secretion uB and total first phase insulin 
above basal AUC10 are likely to be very accurate, peak secretion rate Smax may be 
underestimated due to lack of samples in the first five minutes after glucose injection. 
Additional modelling could improve this artefact. Since this error is systematic, 
comparison between tests remains valid. Considered alongside IS data, help to provide a 
clear indication of the pathophysiology at any given state of the disease process. For 
example, an increased basal insulin secretion and blunted first phase response typically 
Page 16 of 40 
represents a fairly early stage in the progression of insulin resistance, as can be seen in 
Subject 16 (Figure 3 in Appendix C). In addition to the quantitative metrics, these 
concentration profiles resulting from the DISST provide further valuable diagnostic data 
on an individual’s metabolic status. 
 
While the administration of insulin 10 minutes after glucose has clear benefits in 
identifiability of SI, its limitations are in suppressing endogenous second phase insulin 
secretion (36). A reliable estimation of second phase insulin secretion is thus not possible 
with the DISST in the current short protocol. A larger time gap between glucose and 
insulin administration would be required for second phase estimation.   
 
Overall, this pilot study showed that the DISST is feasible to perform in vivo and the 
model and protocol assumptions discussed in detail in Appendix A are valid. The  
integrated approach combining a customized protocol, model and identification method 
has shown good performance in matching the results previously obtained in a Monte 
Carlo study (18). 
 
The full DISST protocol presented here can be completed in 50-60 minutes, which is 
appreciably shorter than the EIC (min 2-4 hours) and the IVGTT (3 hours). A single 
fasting blood test or OGTT is cheaper and simpler, but provide no dynamic information 
regarding the disease process. Instead, the benefit of the test is its accuracy and richness 
of information not obtainable with other simple tests. In addition to providing an 
indication of insulin secretion and sensitivity, the DISST has considerable potential for 
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use as an accurate monitoring tool in metabolic studies and monitoring drug or lifestyle 
intervention programs. The ability to reduce the DISST’s duration to ~30 minutes 
without any loss of performance will make it a more viable alternative to the EIC and 
IVGTT.  
 
Optimal sample size power calculations for a clinical validation study of the DISST 
compared to the EIC were performed using the cross-over study method described by 
Hauschke et al. (37) based on the expected accuracies in repeatability obtained from this 
pilot study. The method calculates the minimal sample size required to show clinical 
equivalence of two different tests. An optimal number of subjects required to show 
equivalence between both metrics within ±10% was determined to be between 24-49. A 
safe choice would thus be at least 50 subjects encompassing a wide range of individuals 
to ensure a broad spectrum of insulin sensitivities. The design of such a validation study 
should also ensure that both tests are performed only a few days apart to minimise errors 
introduced by natural variability. This validation study is currently ongoing, based on 
these pilot trial results. 
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Conclusions 
The clinical pilot study of a new Dynamic Insulin Sensitivity and Secretion Test (DISST) 
has been presented. The DISST was previously designed and verified in Monte Carlo 
simulation and shown to be potentially repeatable and practicable in a clinical setting. 
This clinical pilot trial confirmed these simulated results and provided further insight on 
expected variability due to different dosing and unaccounted physiological variability. 
  
Different insulin and glucose dosing can affect estimated outcomes, but these effects did 
not achieve statistical significance in this pilot study. Repeatability was within expected 
ranges of 6.0-19.8% (2SD) identified in the previous Monte Carlo study (18) and shows 
good potential to correlate well to the EIC in clinical validation. Given the performance 
and practical aspects, a dose of 5-10g glucose and 0.5-1U insulin is recommended for 
further application of the protocol. This low level of dosing ensures a more physiological 
state and less affect on counter-regulatory responses. In practical application, the protocol 
proved to be robust, and can be performed by a single person. Further reduction in the 
number of blood samples and test duration is possible. 
 
Finally, this pilot study provided the results necessary to conservatively power a 
validation trial versus the EIC at N=50+ subjects, which is now underway.  
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Appendix A 
Specific differences between DISST and IVGTT 
At a first glance, the DISST looks very similar to an insulin modified IVGTT. The 
general sequence of the test protocol is similar, followed by a physiological glucose 
model assessment. The IVGTT has been used in many studies and discussed widely, both 
benefits and problems, since the original landmark publication of the minimal model of 
glucose kinetics by Bergman and Cobelli (38). Inspite of its merits, many problems still 
exist with the IVGTT protocol, which constrain its use to a research only environment. 
We have analysed these problems and have attempted to design an insulin sensitivity test 
that is based on the IVGTT concept, but can be used in a clinical setting under 
physiological conditions and dosing. Such a test can enable more accurate insulin 
sensitivity testing in a wider group of people. The key differences in protocol, modelling 
and identification are: 
 
1. Clinical Protocol 
A clinical protocol that is relatively simple to perform was a key objective for the 
development of the DISST. The three main aspect of improvement that were identified 
are the duration, the sampling frequency and the analytes.  
• To achieve a shorter duration than the IVGTT, ie less than 60 minutes, only the 
initial response after insulin administration is to be analyzed. This section of the 
glucose decay curve is mainly attributable to an insulin dependent uptake, due to the 
relatively high concentration of plasma insulin. Furthermore, the counterregulatory 
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glucagon response leading to an increase in EGP is not yet marked and does not 
strongly affect the sampled glucose concentrations. This time reduced data set also 
better matches model assumptions, avoiding misidentification of certain parameters, 
such as insulin-independent glucose uptake pG. In fact, the aspect mentioned here has 
been recognized to also clearly improve Minimal Model fitting of IVGTT data (39).  
• The highly transient dynamics in the first 10 minutes after glucose or insulin 
administration are strongly affected by intravascular mixing, as can be seen in Figure 
4 in which blood samples were taken from both arms during a DISST test. These 
effects have been observed to affect model fitting before, but were mainly attributed 
to a mono-compartmental undermodelling approach (13, 40, 41). High frequency of 
sampling as performed in the first 10-20 minutes of the IVGTT (1-2 minutes) adds to 
data resolution, but is difficult to perform, especially by a single person, due to the 
practical aspects involved in sampling and keeping track of timing. In our experience, 
a sample every 5 minutes is feasible, better every 10 minutes if less transient 
dynamics are observed. By disregarding the initial 10 minutes after glucose or insulin 
administration, the DISST does not only avoid overfitting of unmodelled kinetics, but 
also concentrates on the latter part of the data which better matches the model 
structure of a single glucose compartment (40), avoiding parameter 
misidentifications. 
• Testing and modelling of analytes commonly tested by laboratories (glucose, insulin, 
C-peptide) increases the practical use of the test. Use of glucose tracers, which can be 
used to estimate EGP (42, 43) could improve the performance of the DISST, but add 
complexity and cost, and were thus purposefully avoided. 
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2. Modelling 
Accuracy of identified model parameters can be improved by ensuring the model used 
matches the kinetics and dynamics observed and fitted in the data. Problems with 
Minimal Model fits of IVGTT data have commonly been attributed to undermodelling 
(13, 40). Whether the problem is undermodelling or overfitting of unmodelled effects 
remains to be debated. The model used in the DISST has been adapted from the original 
Minimal Model to better match observed glucose and insulin behaviour at the reduced 
sampling protocol, and to attempt to reduce misidentification issues observed in the past 
(13, 44). Furthermore, a modelling approach has been followed that attempts to match 
assumptions made in the EIC to ensure good correlation with this gold standard test. 
These modelling aspects include: 
• Single compartment glucose kinetics: By acknowledging intravascular mixing and 
disregarding the first 10 minutes of the glucose decay curve, the DISST approach 
concentrates on the latter part of the decay curve, which follows a mono-exponential 
decay and can be identified well with a single compartment model. This approach 
avoids the use of glucose tracers and the requirement of more frequent sampling to 
identify the fast exponential. 
• Insulin independent clearance pG fixed: Robust identification of pG requires a glucose 
decay signal in which insulin concentrations are low. As such a state is not existent 
during the chosen protocol, the value of pG is fixed at a value identified in other 
studies (40, 44-46). This is a well recognized problem with the original Minimal 
Model, which identifies SG from the final stages of the IVGTT in which insulin is 
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low. As counterregulatory effects lead to increased EGP at this stage, SG incorporates 
this effect and is clearly overestimated (13, 39, 42). The DISST value of pG=0.004 
min-1 is lower than commonly found Minimal Model values, because it only 
represents insulin independent uptake, and does not lump suppression of EGP and 
basal glucose uptake into the same parameter (46).   
• Constant endogenous glucose production EGP: EGP can only be estimated with the 
use of tracers (42, 47), and due to the lack of tracers, cannot be estimated in the 
DISST. To minimize inter-subject variability by adding this dynamic, EGP is kept 
constant at a value estimated from the basal state. This assumption is likely a source 
of error, but the suppression effect at low insulin dosing is expected to be reduced at 
the low doses used in the DISST (48). Monte Carlo simulations of this unmodelled 
effect showed only a small influence on the overall estimation of SI (18). 
• Physiologic insulin kinetics: By applying a physiologic insulin kinetics model, the 
estimated concentration of interstitial insulin, driving glucose uptake by the cells (36), 
can be used directly to estimate insulin sensitivity SI. A constant steady state 
concentration ratio of Qss/Iss=1/2 is chosen (49, 50) to a-priori identify the diffusion 
rate nI between both insulin compartments. This constraint removes another source of 
inter-subject variability, and ensures a closer model match to the assumptions of the 
EIC. 
 
• Insulin clearance nL constant: Hepatic insulin clearance nL has been postulated to be 
variable, particularly at the early stage of an IVGTT in which first phase insulin 
secretion is very large (51). This is likely due to a saturation of the receptor-based 
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clearance pathway (52, 53), and is dependent on the magnitude of the first phase 
response. In the DISST, SI estimation is mostly influenced by the insulin signal after 
insulin administration and it is very unlikely that a constant nL will have a significant 
effect on it. 
 
3. Model Identification 
The model identification approach is a very important component of an integrated model-
based diagnostic method. The goal is to ensure a robust overall parameter estimation that 
requires minimal human intervention and still delivers repeatable and reliable results. The 
DISST has been designed to correlate well with the Euglycaemic clamp (EIC), by 
attempting to assess similar physiologic effects, while requiring a shorter and more 
physiologic protocol. The key model identification aspects to achieve this are: 
• Constrain variability to SI: Insulin independent clearance, pG, is fixed at a population 
value, as explained before. This ensures, that the glucose decay is purely attributed to 
insulin mediated effects, represented by SI, matching EIC assumptions. 
• Concentration on strong insulin signal: By concentrating parameter estimation on data 
periods with high insulin concentrations, robustness of SI estimation is improved. Due 
to the external administration of insulin, identification problems in low-sensitivity 
groups, commonly reported in the IVGTT (22, 23, 54) are eliminated. 
• Convex fitting method: The integral-based method used in the DISST is a convex 
parameter identification method that is not starting point dependent (35). Due to the 
integration steps involved, the method further acts as a low pass filter, reducing the 
effects of measurement noise. 
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Appendix B 
The models and methods used to fit the experimentally sampled data are shown here. 
More details on the development of the models and the fitting method employed can be 
found in (18-20, 35, 55). 
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Where G(t) represents plasma glucose concentration, GB basal plasma glucose, VG 
glucose distribution volume, P(t) glucose input into plasma, SI insulin sensitivity, pGU 
non-insulin dependent glucose uptake, EGP(t) endogenous glucose production, I(t) 
plasma insulin, Q(t) interstitial insulin, VP plasma volume, VQ interstitial volume, uex 
exogenous insulin input into plasma, uen pancreatic insulin secretion, nK renal insulin 
clearance rate, nL hepatic insulin clearance rate, nI diffusion constant for insulin transport 
between plasma and interstitium, xL fractional first pass hepatic extraction of pancreatic 
insulin, αI hepatic insulin clearance saturation, nC insulin clearance at tissue cells, C(t) 
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plasma C-peptide, Y(t) interstitial C-peptide, k1-k2 transport rates between C-peptide 
compartments, k3 renal clearance of C-peptide. 
 
The pharmacokinetic (PK) and pharmacodynamic (PD) models shown in Equations (3) – 
(7) are fitted to the sampled profiles of C-peptide, insulin and glucose to obtain model-
based information about the physiological response. The fitting process is performed in 
three steps: 
 
1. Step 1, insulin secretion: Estimation of pancreatic insulin secretion uen(t) is 
performed with the model and methods presented by Eaton et al (55) and Van 
Cauter et al (56). Estimation of insulin secretion rate is performed with an 
integral-based identification method (35) resulting in a minute-wise step function 
of secretion rate. From this result, insulin secretory performance of the pancreas 
can be assessed in basal state, and during first phase secretion in response to an 
intravenous glucose loading. Values calculated in this study are basal secretion 
rate uB (pmol/min), total insulin secreted over basal in the first 10 minutes after 
glucose injection AUC10 (Area Under Curve, in pmol), and peak first phase 
secretion rate Smax (pmol/min). 
 
2. Step 2, insulin kinetics: Insulin kinetics model parameters are estimated by fitting 
the model to the insulin profile data as described in (19). Briefly, model 
parameters are estimated a-priori where possible, using parallels to C-peptide 
kinetics, and remaining key parameters nL and xL estimated from the insulin 
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profile. Estimated pancreatic secretion profile uen(t) from Step 1 is used as input 
to the insulin PK model. The fitting method employed is again the integral-based 
approach (19, 35), which has the advantage of being convex and less sensitive to 
assay variability. 
 
3. Step 3, glucose pharmacodynamics: Insulin sensitivity SI is estimated by fitting 
the glucose PK model to the glucose profile, using modelled interstitial insulin 
Q(t) from Step 2 and known glucose administration P(t). Non-insulin dependent 
glucose uptake pGU cannot be identified reliably given the strong insulin signal in 
this experimental protocol. It was thus kept constant at a population value of 
pGU=0.004 min-1 (46, 57) to avoid well known mis-identification problems 
encountered by others (13). Endogenous glucose production EGP cannot be 
measured easily and is assumed to stay constant throughout the test at a steady 
state value calculated from Equation 3, EGP=SIGBQB, with QB being basal 
interstitial insulin. A constant assumption for EGP ensures the bias of this 
unkown dynamic effect to be systematic, compared to a nonlinear assumption that 
would introduce additional inter-subject variability to the outcome. 
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Appendix C 
Diagnostic relevance 
Figure 3 shows example results of the full DISST analysis on three subjects, including 
Normal Glucose Tolerant (NGT), Impaired Fasting Glucose (IFG) and Type 2 Diabetes 
(Type2). 
 
The progression of the disease can be visualised well on the examples shown in Figure 3. 
The NGT example, Subject 14, has an insulin sensitivity of SI=11.7×10−4 l/mU/min, a 
fasting glucose level of 81.0 mg/dl and fasting insulin level of 20.8 pmol/l. Basal insulin 
secretion rate is uB=146.5 pmol/min. The first phase β-cell response to a bolus injection 
of glucose is very distinct and large, peaking at Smax= 1278 pmol/min above the basal rate 
uB and releasing a total amount of insulin above the basal rate of AUC10= 4841 pmol. The 
first phase insulin secretion lasts about 5-10 minutes, after which the secretion rate 
immediately drops back to nearly its basal rate. 
 
The second example shows an IFG individual, Subject 16. IS is very low at SI=3.2×10−4 
l/mU/min, fasting glucose is elevated at 113.4 mg/dl and fasting insulin is also elevated at 
115.3 pmol/l. Basal insulin secretion rate is three times as high as in the NGT subject, at 
uB = 460 pmol/min. In response to the glucose bolus, the pancreas increases its output, 
but a distinct first phase secretion peak is not pronounced. Insulin secretion peaks at Smax 
= 569 pmol/min above its basal secretion rate uB and continues to produce at this rate 
until the end of the test. The β-cells can only release additional AUC10 = 4014 pmol over 
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the basal rate during the first phase. The pancreas is not able to fully compensate the low 
IS and blood glucose levels drop only slowly. In addition to low IS, significant damage in 
β-cell function is evident in this subject. 
 
The third example shows Subject 11, who has been diagnosed with type 2 diabetes. IS is 
higher than in the IFG example at SI=6.7×10−4 l/mU/min, which could be due to lasting 
effects of Metformin, normally taken by this subject. The fasting glucose level is at 122.4 
mg/dl just below the type 2 diabetes diagnostic threshold of 126 mg/dl (58), and fasting 
insulin is elevated at 9.2 mU/l. Basal insulin secretion rate is uB= 235.4 pmol/min not 
nearly as high as in the IFG subject, a possible sign of β-cell exhaustion. Insulin secretion 
rate is slightly increased in response to the glucose bolus, but only AUC10= 1577 pmol 
are produced above the basal rate uB, with a secretion peak of only Smax= 201 pmol/min 
above the basal rate. The strongly diminished β-cell function cannot compensate for the 
insulin resistance, resulting in fasting hyperglycaemia.  
  
Page 30 of 40 
References 
1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible 
for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular 
disease. Diabetes Care. 1991 Mar;14(3):173-94. 
2. Ferrannini E. Insulin resistance is central to the burden of diabetes. Diabetes Metab 
Rev. 1997 Jun;13(2):81-6. 
3. Martin BC, Warram JH, Krolewski AS, Bergman R, Soeldner JS, Kahn CR. Role of 
glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 
25-year follow-up study. Lancet. 1992 Oct 17;340(8825):925-9. 
4. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in prevalence of 
risk factors for cardiovascular disease and type 2 diabetes in obese individuals: 
impact of differences in insulin sensitivity. Archives Internationales De Physiologie 
De Biochimie Et De Biophysique. 2007;167:642-8. 
5. Scheen AJ, Paquot N, Castillo MJ, Lefebvre PJ. How to measure insulin action in 
vivo. Diabetes Metab Rev. 1994;10(2):151-88. 
6. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among 
the methods. J Clin Endocrinol Metab. 2000 Dec;85(12):4426-33. 
7. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for 
quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-
23. 
8. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998 
Jul;16(7):895-906. 
9. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, et al. 
Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with 
euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 
1989 Feb;68(2):374-8. 
10. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin 
sensitivity and pancreatic responsivity from the frequently sampled intravenous 
glucose tolerance test. Comput Methods Programs Biomed. 1986 Oct;23(2):113-22. 
11. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Y.-D. IC, et al. A 
comparison between the minimal model and the glucose clamp in the assessment of 
insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 1994;43:1114-
21. 
12. Galvin P, Ward GM, Walters JM, Pestell R, Koschmann M, Vaag A, et al. A simple 
method for quantitation of insulin sensitivity and insulin release form an intravenous 
glucose tolerance test. Diabet Med. 1992;9(10):921-8. 
13. Caumo A, Vicini P, Zachwieja JJ, Avogaro A, Yarasheski K, Bier DM, et al. 
Undermodeling affects minimal model indexes: insights from a two-compartment 
model. Am J Physiol. 1999 Jun;276(6 Pt 1):E1171-93. 
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-
9. 
Page 31 of 40 
15. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. 
Quantitative insulin sensitivity check index: a simple, accurate method for assessing 
insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-010. 
16. ADA. Economic consequences of diabetes mellitus in the U.S. in 1997. American 
Diabetes Association. Diabetes Care. 1998 Feb;21(2):296-309. 
17. McAuley KA, Mann JI, Chase JG, Lotz TF, Shaw GM. Point: HOMA - Satisfactory 
for the Time Being: HOMA: the best bet for the simple determination of insulin 
sensitivity, until something better comes along. Diabetes Care. 2007;30(9):2411-3. 
18. Lotz T, Chase JG, McAuley KA, Shaw GM, Wong J, Lin J, et al. Monte Carlo 
analysis of a new model-based method for insulin sensitivity testing. Computer 
Methods and Programs in Biomedicine. 2008;89:215-25. 
19. Lotz T, Chase JG, Lin J, Wong XW, Hann CE, McAuley KA, et al., editors. Integral-
Based Identification of a Physiological Insulin and Glucose Model on Euglycaemic 
Clamp Trials. 14th IFAC Symposium on System Identification (SYSID 2006); 2006 
March 29-31; Newcastle, Australia: IFAC. 
20. Lotz T. High resolution clinical model-based assessment of insulin sensitivity [PhD 
Thesis]: University of Canterbury, Christchurch, New Zealand; 2007. 
21. Edsberg B, Herly D, Hildebrandt P, Kuhl C. Insulin bolus given by a sprinkler 
needle: effect on absorption and glycaemic response to a meal. Br Med J (Clin Res 
Ed). 1987 30-May-1987;294(6584):1373-6. 
22. Cobelli C, Pacini G, Toffolo G, Sacca L. Estimation of insulin sensitivity and 
glucose clearance from minimal model: new insights from labeled IVGTT. Am J 
Physiol. 1986 May;250(5 Pt 1):E591-8. 
23. Krudys KM, Kahn SE, Vicini P. Population approaches to estimate minimal model 
indexes of insulin sensitivity and glucose effectiveness using full and reduced 
sampling schedules. Am J Physiol Endocrinol Metab. 2006;291(4):E716-23. 
24. Prigeon RL, Roder ME, Porte D, Jr., Kahn SE. The effect of insulin dose on the 
measurement of insulin sensitivity by the minimal model technique. Evidence for 
saturable insulin transport in humans. J Clin Invest. 1996 Jan 15;97(2):501-7. 
25. Chase JG, Shaw GM, Lin J, Doran CV, Bloomfield M, Wake GC, et al. Impact of 
Insulin-Stimulated Glucose Removal Saturation on Dynamic Modelling and Control 
of Hyperglycaemia. International Journal of Intelligent Systems Technologies and 
Applications (IJISTA). 2004;1(1/2):79-94. 
26. Chase J, Shaw GM, Wong XW, Lotz T, Lin J, Hann CE. Model-based Glycaemic 
Control in Critical Care - A review of the state of the possible. Biomedical Signal 
Processing & Control. [review and tutorial].  2006;1(1):3-21. 
27. Greisen J, Juhl CB, Grofte T, Vilstrup H, Jensen TS, Schmitz O. Acute pain induces 
insulin resistance in humans. Anesthesiology. 2001 Sep;95(3):578-84. 
28. Minaker KL, Flier JS, Landsberg L, Young JB, Moxley RT, Kingston WJ, et al. 
Phenytoin-induced improvement in muscle cramping and insulin action in three 
patients with the syndrome of insulin resistance, acanthosis nigricans, and acral 
hypertrophy. Arch Neurol. 1989;46(9):981-5. 
29. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in 
human glucose regulation. Endocr Rev. 1997 Oct;18(5):716-38. 
Page 32 of 40 
30. Hollenbeck CB, Reaven G. Treatment of patients with non-insulin-dependent 
diabetes mellitus: diabetic control and insulin secretion and action after different 
treatment modalities. Diabet Med. 1987;4(4):311-6. 
31. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, 
et al. Intensive Insulin Therapy in the Medical ICU. N Engl J Med. [Original 
Article].  2006 Feb. 2;354(5):449-61. 
32. Trout KK, Homko C, Tkacs NC. Methods of measuring insulin sensitivity. 
Biological Research for Nursing. 2007;8(4):305-18. 
33. Nishida Y, Tokuyama K, Nagasaka S, Higaki Y, Shirai Y, Kiyonaga A, et al. Effect 
of moderate exercise training on peripheral glucose effectiveness, insulin sensitivity, 
and endogenous glucose production in healthy humans estimated by a two-
compartment-labeled minimal model. Diabetes. 2004 Feb;53(2):315-20. 
34. O'Gorman DJ, Karlsson HKR, McQuiad S, Yousif O, Rahman Y, Gasparro D, et al. 
Exercise training increases insulin-simulated glucose disposal and GLUT4 
(SLC2A4) protein content in patients with type 2 diabetes. Diabetologia. 
2006;49(12):2983-92. 
35. Hann CE, Chase JG, Lin J, Lotz T, Doran CV, Shaw GM. Integral-based parameter 
identification for long-term dynamic verification of a glucose-insulin system model. 
Comput Methods Programs Biomed. 2005 Mar;77(3):259-70. 
36. Jefferson LS, Cherrington A. The endocrine pancreas and regulation of metabolism. 
Goodman HM, editor. Oxford: Oxford University Press; 2001. 
37. Hauschke D, Kieser M, Diletti E, Burke M. Sample size determination for proving 
equivalence based on the ratio of two means for normally distributed data. Statistics 
in Medicine. 1999;18:93-105. 
38. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin 
sensitivity. Am J Physiol. 1979 Jun;236(6):E667-77. 
39. Callegari T, Caumo A, Cobelli C. Bayesian two-compartment and classic single-
compartment minimal models: comparison on insulin modified IVGTT and effect of 
experiment reduction. IEEE Trans Biomed Eng. 2003 Dec;50(12):1301-9. 
40. Regittnig W, Trajanoski Z, Leis HJ, Ellmerer M, Wutte A, Sendlhofer G, et al. 
Plasma and interstitial glucose dynamics after intravenous glucose injection: 
evaluation of the single-compartment glucose distribution assumption in the minimal 
models. Diabetes. 1999;48(5):1070-81. 
41. Caumo A, Vicini P, Cobelli C. Is the minimal model too minimal? Diabetologia. 
1996 August 1996;38(8):997-1000. 
42. Caumo A, Cobelli C. Hepatic glucose production during the labeled IVGTT: 
estimation by deconvolution with a new minimal model. Am J Physiol. 1993 
May;264(5 Pt 1):E829-41. 
43. Hovorka R, Shojaee-Moradie F, Carroll PV, Chassin LJ, Gowrie IJ, Jackson NC, et 
al. Partitioning glucose distribution/transport, disposal, and endogenous production 
during IVGTT. Am J Physiol Endocrinol Metab. 2002 May;282(5):E992-1007. 
44. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose 
disappearance in subjects with IDDM. Discordance between experimental results and 
minimal model analysis. Diabetes. 1994;43(7):890-6. 
Page 33 of 40 
45. DelPrato S, Matsuda M, Simonson DC, Groop LC, Sheehan P, Leonetti F, et al. 
Studies on the mass action effects of glucose in NIDDM and IDDM: evidence for 
glucose resistance. Diabetologia. 1997;40(6):687-97. 
46. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN. Role of glucose 
effectiveness in the determination of glucose tolerance. Diabetes Care. 1996 
Sep;19(9):1018-30. 
47. Vicini P, Caumo A, Cobelli C. Glucose effectiveness and insulin sensitivity from the 
minimal models: consequences of undermodeling assessed by Monte Carlo 
simulation. IEEE Trans Biomed Eng. 1999 Feb;46(2):130-7. 
48. Vella A, Reed AS, Charkoudian N, Shah P, Basu R, Basu A, et al. Glucose-induced 
suppression of endogenous glucose production: dynamic response to differing 
glucose profiles. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E25-30. 
49. Gudbjornsdottir S, Sjostrand M, Strindberg L, Wahren J, Lonnroth P. Direct 
measurements of the permeability surface area for insulin and glucose in human 
skeletal muscle. J Clin Endocrinol Metab. 2003 Oct;88(10):4559-64. 
50. Sjostrand M, Holmang A, Lonnroth P. Measurement of interstitial insulin in human 
muscle. Am J Physiol. 1999 Jan;276(1 Pt 1):E151-4. 
51. Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C. A minimal model of insulin 
secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol 
Metab. 2006 Jan;290(1):E169-E76. 
52. Thorsteinsson B. Kinetic models for insulin disappearance from plasma in man. Dan 
Med Bull. 1990 Apr;37(2):143-53. 
53. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and 
renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol. 
1983 Jun;244(6):E517-27. 
54. Pillonetto G, Sparacino G, Magni P, Bellazzi R, Cobelli C. Minimal model S(I)=0 
problem in NIDDM subjects: nonzero Bayesian estimates with credible confidence 
intervals. Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E564-73. 
55. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin 
production in man: kinetic analysis using peripheral connecting peptide behavior. J 
Clin Endocrinol Metab. 1980 Sep;51(3):520-8. 
56. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates 
from C-peptide levels. Comparison of individual and standard kinetic parameters for 
C-peptide clearance. Diabetes. 1992 Mar;41(3):368-77. 
57. Del Prato S, Matsuda M, Simonson DC, Groop L, Sheehan P, Leonetti F, et al. 
Studies in the mass action effect of glucose in NIDDM and IDDM: evidence for 
glucose resistance. Diabetologia. 1997;40(6):687-97. 
58. ADA. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2006 
Jan;29(suppl_1):S43-S8. 
 
 
Page 34 of 40 
Table 1: Subject characteristics and tests performed on each subject. * IFG denotes 
subjects who have not been diagnosed with type 2 diabetes (T2D) but who have elevated 
fasting glucose levels > 100 mg/dl, qualifying for an ADA diagnosis of impaired fasting 
glucose (IFG) at the day of the test. 
 
Subj. Gend. Age 
(yrs) 
Weight 
(kg) 
BMI 
(kg/m2) 
Fasting 
glucose 
(mg/dl) 
Fasting 
insulin 
(pmol/L) 
T2D 
or 
IFG* 
Tests Part 
5g 
0.5U 
10g 
1U 
20g 
2U 1 2 
1 f 57 89 33.9 104.4 213.9 IFG   1 1 X  
2 f 59 67 25.5 106.2 9.7 IFG  1 1 X  
3 f 59 87 39.2 84.6 86.8    3   X 
4 f 21 78 25.2 90.0 36.1   1 1  X  
5 m 41 76 21.7 72.0 3.5    2 1 X X 
6 f 45 76 25.4 73.8 11.8    2 1 X  
7 m 55 73 24.1 81.0 30.6   1 1  X  
8 f 51 67 27.2 77.4 9.7   1 1  X  
9 f 35 66 24 86.4 45.8   1 1 X  
10 f 30 50 19.5 75.6 22.2   2 1  X X 
11 f 55 85 30.1 122.4 63.9 T2D 2 1  X X 
12 m 60 76 23.7 79.2 22.2   1    
13 f 48 91 33.4 93.6 66.0    3   X 
14 f 41 111 41.3 81.0 27.1    2 1 X X 
15 m 29 84 25.9 91.0 17.4   2 1  X X 
16 m 49 105 35.1 113.4 115.3 IFG 2 1  X X 
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Table 2: Results from model fit to experimental data from Part 1 of the study. Shown are 
insulin sensitivity SI, change at higher dose ΔSI, basal insulin secretion rate uB, total first 
phase insulin secretion AUC10, change at higher dose ΔAUC10, peak insulin secretion rate 
Smax and change at higher dose ΔSmax. 
low/medium (P=0.50) 
Subject Dose SI [L/mU/min] 
ΔSI 
[%] 
uB 
[pmol/min] 
AUC10 
[pmol] 
ΔAUC10 
[%] 
Smax 
[pmol/min] 
ΔSmax 
[%] 
4 5 g 13.39   136.1 1536   246  
 10 g 16.49 23.1 145.2 1764 14.8 292 18.8 
7 5 g 19.33   172.9 2910   748  
 10 g 18.06 -6.6 171.5 5458 87.5 1061 41.9 
8 5 g 18.64   79.2 2638   608  
 10 g 13.61 -27.0 88.9 5782 119.1 1327 118.0 
10 5 g 43.73   95.1 3330   745  
 10 g 17.40   93.8 4364 25.8 1040  
 5 g 29.19 -52.3 108.3 3611   852 30.2 
11 5 g 6.88   251.4 1400   189  
 10 g 6.73   235.4 1574 16.2 203  
 5 g 5.75 6.5 293.1 1308   220 -0.9 
15 5 g 8.28   138.9 2776   795  
 10 g 7.39   144.5 4501 69.4 1007  
 5 g 8.99 -14.4 153.5 2538   728 32.3 
16 5 g 3.27   435.5 1702   299  
 10 g 3.17   459.8 4011 213.8 569  
 5 g 3.16 -1.4 395.9 856   178 138.6 
mean   -10.3   78.1  54.1 
SD    24.3   71.7  52.7 
medium/high (P=0.87) 
1 10 g 3.13   492.4 2732  435  
  20 g 2.69 -14.1 478.5 7133 161.2 1222 180.9 
2 10 g 19.47   61.8 1214  226  
  20 g 13.43 -31.0 83.3 1563 28.8 271 20.0 
5 10 g 26.45   99.3 2851  529  
 20 g 25.07   75.7 3918 48.5 905  
  10 g 19.97 8.0 77.1 2425   481 79.3 
6 10 g 14.84   118.1 2694  440  
  20 g 12.83 -13.6 119.5 3851 60.9 563 27.9 
14 10 g 11.70   146.5 4837  1278  
 20 g 14.12   132.6 4630 -7.1 1003  
  10 g 11.65 20.9 179.2 5129   1252 -20.7 
mean    -6.0   58.5  57.5 
SD    20.4   62.9  77.6 
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Table 3: Results from model fit to experimental data from Part 2 of the study. Shown are 
insulin sensitivity SI, change at higher dose ΔSI, basal insulin secretion rate uB, total first 
phase insulin secretion AUC10, change at higher dose ΔAUC10, peak insulin secretion rate 
Smax and change at higher dose ΔSmax. 
 
Low dose (5g glucose, 0.5U insulin) (P=0.75) 
Subject SI [L/mU/min] 
ΔSI 
[%] 
uB 
[pmol/min] 
AUC10 
[pmol] 
ΔAUC10 
[%] 
Smax 
[pmol/min] 
ΔSmax 
[%] 
10 43.73   95.1 3330  745  
  29.19 19.9 108.3 3612 4.0 852 6.7 
11 6.88   251.4 1400  189  
  5.75 8.9 293.1 1308 3.4 220 7.6 
15 8.28   138.9 2776  795  
  8.99 4.1 153.5 2538 4.5 728 4.4 
16 3.27   435.5 1702  299  
  3.16 1.7 395.9 856 33.1 178 25.3 
Medium dose (10g glucose, 1U insulin) (P=0.56) 
3 10.18   236.8 8390  1679  
 8.59   269.5 9892  1879  
  7.37 16.8 300.0 9140  8.2 2195  14.4 
5 26.45   99.3 2851  529  
  19.97 14.0 77.1 2425 8.1 481 4.7 
13 16.31   247.2 3155  506  
 13.51   251.4 3782  845  
  21.20 24.7 236.8 4125  11.9 706  23.2 
14 11.70   146.5 4837  1278  
  11.65 0.2 178.5 5129 2.9 1252 1.0 
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Figure 1: Part 1 dose-dependent variability in insulin sensitivity SI as a function of SI. 
Black squares show relative percentile differences in estimated SI values between the low 
and medium dose protocols, white squares between the medium and high dose protocols. 
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Figure 2: Part 2, accuracy in repeatability of estimated insulin sensitivity SI as a function 
of SI. Black circles show relative percentile differences around the mean of estimated SI 
values during the low dose protocol, white circles during the medium dose protocol. 
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Figure 3: The exemplary test results using 10g glucose and 1 U insulin on a normal 
glucose tolerant (NGT, top), impaired fasting glucose (IFG, middle) and Type 2 
diabetes subject (Type 2, bottom). Shown are, from left to right, the estimated 
endogenous insulin secretion rate with overlaid plasma C-peptide concentration, the 
plasma insulin concentration and the blood glucose concentration. Samples are 
shown with error bars and areas show the model fits. The scale in the first column 
shows pmol/min for insulin secretion rate, and pmol/L for plasma C-peptide 
concentration. 
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Figure 4: Effects of mixing. Shown are samples taken from both arms of the same subject 
after administration of glucose and insulin. Concentrations take about 10-15 minutes to 
equalize in both arms, a clear sign of intravascular mixing. 
 
